Back to Results
First PageMeta Content
Pharmacology / Rituximab / B-cell chronic lymphocytic leukemia / Genmab / CD20 / Fludarabine / Leukemia / Medicine / Ofatumumab / Oncology


U.S. Food and Drug Administration Notice: Archived Document
Add to Reading List

Open Document

File Size: 901,89 KB

Share Result on Facebook

City

Houston Michael Keating / /

Company

GlaxoSmithKline / Glaxosmithkline plc / /

Event

FDA Phase / /

Facility

Karolinska Institute / Long Island Jewish Medical Center / /

IndustryTerm

treatment of patients with chronic lymphocytic leukemia / /

MedicalCondition

fludarabine-refractory disease / chronic lymphocytic leukemia / common leukemia / /

Organization

Karolinska Institute / Division of Hematology/Oncology / Injection GlaxoSmithKline Presentation Oncologic Drugs Advisory Committee / Jewish Medical Center / U.S. Food and Drug Administration / UCSD / /

Person

Houston Thomas Kipps / Stockholm Kanti Rai / William G. Wierda / Michael Keating / La Jolla Anders Österborg / Michael Arning / Concluding Remarks Debasish Roychowdhury / Debasish Roychowdhury / Brien / /

Product

GlaxoSmithKline 2 External Participants / Proposed Indication ARZERRA™ (ofatumumab) / /

ProvinceOrState

M.B. / /

SocialTag